Oncolytic viruses for cancer immunotherapy

Show full item record



Permalink

http://hdl.handle.net/10138/318395

Citation

Hemminki , O , dos Santos , J M & Hemminki , A 2020 , ' Oncolytic viruses for cancer immunotherapy ' , Journal of Hematology & Oncology , vol. 13 , no. 1 , 84 . https://doi.org/10.1186/s13045-020-00922-1

Title: Oncolytic viruses for cancer immunotherapy
Author: Hemminki, Otto; dos Santos, Joao Manuel; Hemminki, Akseli
Contributor organization: Research Programs Unit
Clinicum
TRIMM - Translational Immunology Research Program
University of Helsinki
Urologian yksikkö
Helsinki University Hospital Area
HUS Abdominal Center
Medicum
Department of Oncology
HUS Comprehensive Cancer Center
Date: 2020-06-29
Language: eng
Number of pages: 15
Belongs to series: Journal of Hematology & Oncology
ISSN: 1756-8722
DOI: https://doi.org/10.1186/s13045-020-00922-1
URI: http://hdl.handle.net/10138/318395
Abstract: In this review, we discuss the use of oncolytic viruses in cancer immunotherapy treatments in general, with a particular focus on adenoviruses. These serve as a model to elucidate how versatile viruses are, and how they can be used to complement other cancer therapies to gain optimal patient benefits. Historical reports from over a hundred years suggest treatment efficacy and safety with adenovirus and other oncolytic viruses. This is confirmed in more contemporary patient series and multiple clinical trials. Yet, while the first viruses have already been granted approval from several regulatory authorities, room for improvement remains. As good safety and tolerability have been seen, the oncolytic virus field has now moved on to increase efficacy in a wide array of approaches. Adding different immunomodulatory transgenes to the viruses is one strategy gaining momentum. Immunostimulatory molecules can thus be produced at the tumor with reduced systemic side effects. On the other hand, preclinical work suggests additive or synergistic effects with conventional treatments such as radiotherapy and chemotherapy. In addition, the newly introduced checkpoint inhibitors and other immunomodulatory drugs could make perfect companions to oncolytic viruses. Especially tumors that seem not to be recognized by the immune system can be made immunogenic by oncolytic viruses. Logically, the combination with checkpoint inhibitors is being evaluated in ongoing trials. Another promising avenue is modulating the tumor microenvironment with oncolytic viruses to allow T cell therapies to work in solid tumors. Oncolytic viruses could be the next remarkable wave in cancer immunotherapy.
Subject: Adenovirus
Oncolytic
Tumor
Cancer
Immunotherapy
Review
Immunology
Immune system
Immunosupression
ANTITUMOR IMMUNE-RESPONSES
COLONY-STIMULATING FACTOR
NECROSIS-FACTOR-ALPHA
PHASE-I TRIAL
OVARIAN-CANCER
GENE-TRANSFER
CELL THERAPY
GM-CSF
TALIMOGENE LAHERPAREPVEC
REPLICATION-COMPETENT
3122 Cancers
Peer reviewed: Yes
Rights: cc_by
Usage restriction: openAccess
Self-archived version: publishedVersion


Files in this item

Total number of downloads: Loading...

Files Size Format View
s13045_020_00922_1.pdf 1.750Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record